OS Therapies Incorporated (OSTX) Price & Analysis

Compare

160 Followers

OSTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.12 - $7.00

Previous CloseN/A

Volume28.07K

Average Volume (3M)667.30K

Market Cap

$67.99M

Enterprise Value$34.55M

Total Cash (Recent Filing)$5.53M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.31

Next Earnings

Aug 14, 2025

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding31,624,077

10 Day Avg. Volume538,068

30 Day Avg. Volume667,302

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.51

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.06

Forecast

1Y Price Target

$12.50

Price Target Upside481.40% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessPositive updated interim 2-year overall survival data from the P2b trial showed 66.6% of OST-HER2 treated patients achieved survival compared to 40% for historical control.

Regulatory AdvancementThe company continues to make progress toward a potential rolling BLA filing, including an End-of-Phase 2 meeting with FDA scheduled, which suggests a favorable outlook for accelerated approval.

Bears Say

Financial PerformanceOS Therapies reported a net loss of ($3.8M) and ended the period with $3.1M in cash, indicating a need to raise additional capital in the near-term.

OS Therapies Incorporated News

OS Therapies files $100M mixed securities shelf

16:47 EDT OS Therapies (OSTX) files $100M mixed securities shelf Published first on TheFly – the ultimate source...

8d ago

OSTX

OS Therapies files to sell 3.76M shares of common stock for holders

16:33 EDT OS Therapies (OSTX) files to sell 3.76M shares of common stock for holders Published first on...

12d ago

OSTX

OS Therapies CEO Paul Romness sees ‘huge upside potential’

15:06 EDT OS Therapies (OSTX) CEO Paul Romness sees ‘huge upside potential’ Published first on TheFly – the...

30d ago

OSTX

OS Therapies hopes to become commercial biotech in early 2026, CEO says

15:06 EDT OS Therapies (OSTX) hopes to become commercial biotech in early 2026, CEO says Published first on...

30d ago

OSTX

Romness sees potential FDA approval, PVR as key to OS Therapies stock

15:06 EDT Romness sees potential FDA approval, PVR as key to OS Therapies (OSTX) stock Published first on...

30d ago

OSTX

Meet OS Therapies: Fly exclusive interview with CEO Paul Romness

In an exclusive interview, OS Therapies’ (OSTX) CEO Paul Romness met with The Fly to discuss the company,...

30d ago

OSTX

OS Therapies Updates Quorum Rules for Shareholder Meetings

The latest announcement is out from OS Therapies Incorporated ( ($OSTX) ). On August 15, 2025, OS Therapies...

17h ago

OSTX

OS Therapies Delays Q2 2025 Financial Report

OS Therapies Incorporated ( ($OSTX) ) has released a notification of late filing. OS Therapies Incorporated has announced...

1d ago

OSTX

Promising Phase 2b Results and Regulatory Advancements Drive Buy Rating for OS Therapies

OS Therapies Incorporated, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy...

8d ago

OSTX

OS Therapies Raises $4.2M Through Warrant Exercise

An announcement from OS Therapies Incorporated ( ($OSTX) ) is now available. On July 11, 2025, OS Therapies...

1M ago

OSTX

OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on OS Therapies Incorporated and keeping the price...

1M ago

OSTX

OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program

OS Therapies (OSTX) announced it was granted an End of Phase 2 Meeting by the United States Food...

1M ago

OSTX

Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on OS Therapies Incorporated and keeping the price...

1M ago

OSTX

OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2

OS Therapies (OSTX) announced positive 1-year event free survival, overall survival and safety clinical trial data updates from...

2M ago

OSTX

OSTX FAQ

What was OS Therapies Incorporated’s price range in the past 12 months?

OS Therapies Incorporated lowest stock price was $1.12 and its highest was $7.00 in the past 12 months.

What is OS Therapies Incorporated’s market cap?

OS Therapies Incorporated’s market cap is $67.99M.

When is OS Therapies Incorporated’s upcoming earnings report date?

OS Therapies Incorporated’s upcoming earnings report date is Aug 14, 2025 which is 2 days ago.

How were OS Therapies Incorporated’s earnings last quarter?

Currently, no data Available

Is OS Therapies Incorporated overvalued?

According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does OS Therapies Incorporated pay dividends?

OS Therapies Incorporated does not currently pay dividends.

What is OS Therapies Incorporated’s EPS estimate?

OS Therapies Incorporated’s EPS estimate is -0.12.

How many shares outstanding does OS Therapies Incorporated have?

OS Therapies Incorporated has 31,624,077 shares outstanding.

What happened to OS Therapies Incorporated’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OS Therapies Incorporated?

Currently, no hedge funds are holding shares in OSTX

OS Therapies Incorporated Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

305.17%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

OS Therapies Incorporated

OS Therapies Incorporated (OSTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the healthcare sector, with a strong emphasis on oncology research and development. Its core products and services include the creation of targeted therapies designed to improve patient outcomes and quality of life through advanced scientific approaches.

OS Therapies Incorporated (OSTX) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

OSTX Stock 12 Month Forecast

Average Price Target

$12.50

▲(481.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","15":"$15","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5,10,15,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,3.0769230769230766,4.403846153846153,5.730769230769231,7.0576923076923075,8.384615384615383,9.711538461538462,11.038461538461538,12.365384615384615,13.692307692307692,15.019230769230768,16.346153846153847,17.673076923076923,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,2.5769230769230766,3.4038461538461537,4.230769230769231,5.0576923076923075,5.884615384615384,6.711538461538462,7.538461538461538,8.365384615384615,9.192307692307692,10.019230769230768,10.846153846153845,11.673076923076923,{"y":12.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,2.076923076923077,2.4038461538461537,2.730769230769231,3.0576923076923075,3.3846153846153846,3.7115384615384617,4.038461538461538,4.365384615384615,4.6923076923076925,5.019230769230769,5.346153846153847,5.673076923076923,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >